Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039499 | 0.92 | CTSK (0.35) | ALDH1A1GAACTSKKMT2APKM | |
| SCHEMBL4039943 | 0.91 | POLB (0.35) | KDM4EALDH1A1GAACTSKKMT2A | |
| SCHEMBL4040674 | 0.90 | POLB (0.37) | KDM4ECYP2C9CYP2C19ALDH1A1KMT2A | |
| SCHEMBL4040595 | 0.89 | CTSK (0.34) | ALDH1A1GAACTSKKMT2APKM | |
| SCHEMBL4042824 | 0.89 | KDM4E (0.40) | KDM4ECYP2C9CYP2C19ALDH1A1GAA | |
| SCHEMBL4043419 | 0.87 | CTSK (0.33) | CTSK | |
| SCHEMBL4040117 | 0.85 | CTSK (0.32) | CTSK | |
| SCHEMBL4043889 | 0.83 | KDM4E (0.41) | KDM4ECYP2C9CYP2C19GAACTSK | |
| SCHEMBL4041828 | 0.83 | CTSK (0.35) | KDM4EALDH1A1GAACTSKKMT2A | |
| SCHEMBL6209026 | 0.82 | KDM4E (0.40) | KDM4ECYP2C9CYP2C19ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| US-11596593-B2 | Oral care composition with cross-linked polymer peroxide | COLGATE-PALMOLIVE COMPANY (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210137815-A1 | Oral Care Composition with Cross-Linked Polymer Peroxide | COLGATE-PALMOLIVE COMPANY (US) | 2021-05-13 | — | — | US | disclosed |
| US-10959936-B2 | Oral care composition with cross-linked polymer peroxide | COLGATE-PALMOLIVE COMPANY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200345615-A1 | Oral Care Composition with Cross-Linked Polymer Peroxide | COLGATE-PALMOLIVE COMPANY (US) | 2020-11-05 | — | — | US | disclosed |
| US-10758472-B2 | Oral care composition with cross-linked polymer peroxide | COLGATE-PALMOLIVE COMPANY (US) | 2020-09-01 | — | — | US | disclosed |
| US-20180333346-A1 | Oral Care Composition with Cross-Linked Polymer Peroxide | COLGATE-PALMOLIVE COMPANY (US) | 2018-11-22 | — | — | US | disclosed |
| US-9895304-B2 | Oral care composition with cross-linked polymer peroxide | COLGATE-PALMOLIVE COMPANY (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170049680-A1 | ORAL CARE COMPOSITION WITH CROSS-LINKED POLYMER PEROXIDE | COLGATE PALMOLIVE CO (US) | 2017-02-23 | — | — | US | disclosed |
| US-9517194-B2 | Oral care composition with cross-linked polymer peroxide | COLGATE-PALMOLIVE COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| EP-1781380-B1 | ORAL CARE COMPOSITION WITH CROSS-LINKED POLYMER PEROXIDE | COLGATE PALMOLIVE CO (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080145321-A1 | ORAL CARE COMPOSITION WITH CROSS-LINKED POLYMER PEROXIDE | COLGATE-PALMOLIVE COMPANY (US) | 2008-06-19 | — | — | US | disclosed |
| CN-101005879-A | Oral care compositions with cross-linked polymer peroxides | COLGATE PALMOLIVE CO (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1781380-A1 | ORAL CARE COMPOSITION WITH CROSS-LINKED POLYMER PEROXIDE | Colgate-Palmolive Company (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| WO-2006026424-A1 | ORAL CARE COMPOSITION WITH CROSS-LINKED POLYMER PEROXIDE | COLGATE-PALMOLIVE COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060045854-A1 | Oral care composition with cross-linked polymer peroxide | COLGATE-PALMOLIVE COMPANY | 2006-03-02 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | KDM4E 3911/4885CYP2C9 80/4885CYP2C19 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.